C-erbB-3 expression in non-small cell lung cancer (NSCLC) patients treated by Erlotinib.

Date publication

janvier 2011

Journal

Anticancer research

Auteurs

Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline

Tous les auteurs :
CsToth I, Anthoine G, Berghmans T, Mascaux C, Paesmans M, Sculier JP, Meert AP

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/21273611

Résumé

The clinical impact of c-erbB-3 has seldom been assessed in patients with non small cell lung cancer (NSCLC).

Mots clés

Adenocarcinoma, drug therapy, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, drug therapy, Carcinoma, Squamous Cell, drug therapy, ErbB Receptors, antagonists & inhibitors, Erlotinib Hydrochloride, Female, Humans, Immunoenzyme Techniques, Lung Neoplasms, drug therapy, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors, therapeutic use, Quinazolines, therapeutic use, Receptor, ErbB-3, metabolism, Survival Rate

Référence

Anticancer Res.. 2011 Jan;31(1):281-5